RegeneRx Publishes Regulatory Update on RGN-259

Rhea-AI Summary

On January 12, 2022, RegeneRx Biopharmaceuticals (OTCQB: RGRX) announced a regulatory progress update for RGN-259, a drug focused on tissue protection and regeneration. The update was published on the company's website, providing stakeholders with insights into the status of RGN-259's development. This move is part of RegeneRx's ongoing efforts to advance its clinical-stage drug programs, aiming to enhance the treatment outcomes for patients.

Positive

• RegeneRx provided an update on the regulatory progress of RGN-259, indicating ongoing development.
• Focus on tissue protection and regeneration positions the company in a growing market.

Negative

• None.

ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's website at www.regenerx.com.

View original content:https://www.prnewswire.com/news-releases/regenerx-publishes-regulatory-update-on-rgn-259-301459520.html

SOURCE RegeneRx Biopharmaceuticals, Inc.

FAQ

What is the latest update on RGN-259 from RegeneRx Biopharmaceuticals?

RegeneRx published an update on RGN-259's regulatory progress on January 12, 2022.

What is RegeneRx Biopharmaceuticals focused on?

RegeneRx is focused on developing therapies for tissue protection, repair, and regeneration.

What stock symbol is associated with RegeneRx Biopharmaceuticals?

The stock symbol for RegeneRx Biopharmaceuticals is RGRX.

Where can I find more information about RegeneRx's regulatory updates?

More information can be found on RegeneRx's official website.